Horizon Therapeutics
Horizon Therapeutics was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.
| Formerly | Horizon Pharma plc |
|---|---|
| Company type | Subsidiary |
Traded as | Nasdaq: HZNP |
| Industry | Pharmaceutical |
| Founded | 2005 |
| Headquarters |
|
Key people | Timothy P. Walbert (Chairman, President & CEO) Paul W. Hoelscher (CFO) |
| Revenue | US$3.63 billion (2022) |
| US$617 million (2022) | |
Net income | US$521 million (2022) |
| Total assets | US$9.11 billion (2022) |
| Total equity | US$5.07 billion (2022) |
Number of employees | 2,115 (2022) |
| Parent | Amgen |
| Website | horizontherapeutics |
| Footnotes / references | |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.